Skip to content
2000
Volume 32, Issue 40
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

To treat diseases like cancer, conventional Paclitaxel (PTX)-based monotherapy treatment regimens are becoming less effective due to the development of resistance. In this aspect, the phytomolecule curcumin (Cur), having ethnopharmacological importance in traditional South Asian remedies, like Ayurveda and Chinese traditional medicine, has been studied as a promising chemo-sensitizing and synergistic partner of PTX.

Aim

This study aimed to evaluate the combined effect of PTX and Cur compared to PTX therapy alone in the and environments.

Materials and Methods

An extensive PubMed search was performed wherein 169 papers were shortlisted and screened to identify 30 studies that have reported the effect of PTX and Cur either , , or both. The pooled Odds Ratio (OR) was calculated at a 95% Confidence Interval (CI) for determining the effect of combination therapy.

Results

The meta-analysis has indicated PTX and Cur combination therapy to be associated with a significant decrease in cell viability (OR: 0.37, 95% CI: 0.27-0.51; < 0.01) and tumor volume (OR: 0.32, 95% CI: 0.15-0.71; = 0.01). Additionally, the effect of this combination on drug-resistant cell lines has exhibited a significant decrease in the odds of cell viability (OR: 0.45, 95% CI: 0.35-0.57; < 0.01).

Conclusion

Overall, the current meta-analysis has shown PTX and Cur combination to effectively inhibit the viability of cancer cells, reduce tumor volume, and diminish the growth of drug-resistant cancer cells.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673313858240826105305
2024-09-05
2025-10-18

  • From This Site

    /content/journals/cmc/10.2174/0109298673313858240826105305
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA. Cancer. J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. DebelaD.T. MuzazuS.G.Y. HeraroK.D. NdalamaM.T. MeseleB.W. HaileD.C. KituiS.K. ManyazewalT. New approaches and procedures for cancer treatment: Current perspectives.SAGE Open Med.2021910.1177/2050312121103436634408877
     [Google Scholar]
  3. SchirrmacherV. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review).Int. J. Oncol.201854240741910.3892/ijo.2018.466130570109
     [Google Scholar]
  4. BavaS.V. PuliappadambaV.T. DeeptiA. NairA. KarunagaranD. AntoR.J. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization.J. Biol. Chem.200528086301630810.1074/jbc.M41064720015590651
     [Google Scholar]
  5. AggarwalB.B. ShishodiaS. TakadaY. BanerjeeS. NewmanR.A. Bueso-RamosC.E. PriceJ.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.Clin. Cancer Res.200511207490749810.1158/1078‑0432.CCR‑05‑119216243823
     [Google Scholar]
  6. GantaS. AmijiM. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.Mol. Pharm.20096392893910.1021/mp800240j19278222
     [Google Scholar]
  7. KangH.J. LeeS.H. PriceJ.E. KimL.S. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.Breast J.200915322322910.1111/j.1524‑4741.2009.00709.x19645775
     [Google Scholar]
  8. Gallego-JaraJ. Lozano-TerolG. Sola-MartínezR.A. Cánovas-DíazM. de Diego PuenteT. A compressive review about taxol®: history and future challenges.Molecules20202524598610.3390/molecules2524598633348838
     [Google Scholar]
  9. Esparza-lópezJ. LongoriaO. De La Cruz-escobarE. Garibay-díazJ. León-rodríguezE. Ibarra-sánchezM. Paclitaxel resistance is mediated by NF-κB on mesenchymal primary breast cancer cells.Oncol. Lett.20212325010.3892/ol.2021.1316834992683
     [Google Scholar]
  10. YusufR. DuanZ. LamendolaD. PensonR. SeidenM. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.Curr. Cancer Drug Targets20033111910.2174/156800903333375412570657
     [Google Scholar]
  11. DasA.P. AgarwalS.M. Recent advances in the area of plant-based anti-cancer drug discovery using computational approaches.Mol. Divers.202428290192510.1007/s11030‑022‑10590‑736670282
     [Google Scholar]
  12. AtanasovA.G. ZotchevS.B. DirschV.M. SupuranC.T. Natural products in drug discovery: advances and opportunities.Nat. Rev. Drug Discov.202120320021610.1038/s41573‑020‑00114‑z33510482
     [Google Scholar]
  13. ChopraB. DhingraA.K. Natural products: A lead for drug discovery and development.Phytother. Res.20213594660470210.1002/ptr.709933847440
     [Google Scholar]
  14. NewmanD.J. CraggG.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019.J. Nat. Prod.202083377080310.1021/acs.jnatprod.9b0128532162523
     [Google Scholar]
  15. MoghadamtousiS.Z. KadirH.A. HassandarvishP. TajikH. AbubakarS. ZandiK. A review on antibacterial, antiviral, and antifungal activity of curcumin.Biomed. Res. Int.2014201418686410.1155/2014/186864
     [Google Scholar]
  16. YadavI.S. NandekarP.P. ShrivastavaS. SangamwarA. ChaudhuryA. AgarwalS.M. Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity.Gene20145391829010.1016/j.gene.2014.01.05624491504
     [Google Scholar]
  17. HewlingsS. KalmanD. Curcumin: a review of its effects on human health.Foods20176109210.3390/foods610009229065496
     [Google Scholar]
  18. ShabbirU. RubabM. DaliriE.B.M. ChelliahR. JavedA. OhD.H. Curcumin, quercetin, catechins and metabolic diseases: the role of gut microbiota.Nutrients202113120610.3390/nu1301020633445760
     [Google Scholar]
  19. YinS.-Y. WeiW.-C. JianF.-Y. YangN.-S. Therapeutic applications of herbal medicines for cancer patientsEvid. Based. Complment. Alternat. Med.2013201330242610.1155/2013/302426
     [Google Scholar]
  20. LinY. ZhangH. NiuT. TangM.L. ChangJ. Discovery of novel indoleamine 2,3-dioxygenase 1 (ido1) and histone deacetylase 1 (hdac1) dual inhibitors derived from the natural product saprorthoquinone.Molecules20202519449410.3390/molecules2519449433007982
     [Google Scholar]
  21. MokhtariR.B. HomayouniT.S. BaluchN. MorgatskayaE. KumarS. DasB. YegerH. Combination therapy in combating cancer.Oncotarget2017823380223804310.18632/oncotarget.1672328410237
     [Google Scholar]
  22. AtanasovA.G. WaltenbergerB. Pferschy-WenzigE.M. LinderT. WawroschC. UhrinP. TemmlV. WangL. SchwaigerS. HeissE.H. RollingerJ.M. SchusterD. BreussJ.M. BochkovV. MihovilovicM.D. KoppB. BauerR. DirschV.M. StuppnerH. Discovery and resupply of pharmacologically active plant-derived natural products: A review.Biotechnol. Adv.20153381582161410.1016/j.biotechadv.2015.08.00126281720
     [Google Scholar]
  23. PatwardhanB. WarudeD. PushpangadanP. BhattN. Ayurveda and traditional Chinese medicine: a comparative overview.Evid. Based Complement. Alternat. Med.20052446547310.1093/ecam/neh14016322803
     [Google Scholar]
  24. DasA.P. SainiS. AgarwalS.M. A comprehensive meta-analysis of non-coding polymorphisms associated with precancerous lesions and cervical cancer.Genomics2022114311032310.1016/j.ygeno.2022.11032335227837
     [Google Scholar]
  25. ZuoS. WangZ. AnX. WangJ. ZhengX. ShaoD. ZhangY. Self-assembly engineering nanodrugs composed of paclitaxel and curcumin for the combined treatment of triple negative breast cancer.Front. Bioeng. Biotechnol.2021974763710.3389/fbioe.2021.74763734504835
     [Google Scholar]
  26. ZhouQ. YeM. LuY. ZhangH. ChenQ. HuangS. SuS. Curcumin improves the tumoricidal effect of mitomycin c by suppressing abcg2 expression in stem cell-like breast cancer cells.PLoS One201510813669410.1371/journal.pone.013669426305906
     [Google Scholar]
  27. AcharyaS. SahooS.K. Sustained targeting of Bcr–Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy.Biomaterials201132245643566210.1016/j.biomaterials.2011.04.04321600647
     [Google Scholar]
  28. BoztasA.O. KarakuzuO. GalanteG. UgurZ. KocabasF. AltuntasC.Z. YazaydinA.O. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells.Mol. Pharm.20131072676268310.1021/mp400101k23730903
     [Google Scholar]
  29. KalluruH. KondaveetiS.S. TelapoluS. KalachaveeduM. Turmeric supplementation improves the quality of life and hematological parameters in breast cancer patients on paclitaxel chemotherapy: A case series.Complement. Ther. Clin. Pract.20204110124710.1016/j.ctcp.2020.10124733099272
     [Google Scholar]
  30. SaghatelyanT. TananyanA. JanoyanN. TadevosyanA. PetrosyanH. HovhannisyanA. HayrapetyanL. ArustamyanM. ArnholdJ. RotmannA.R. HovhannisyanA. PanossianA. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial.Phytomedicine20207015321810.1016/j.phymed.2020.15321832335356
     [Google Scholar]
  31. PunfaW. SuzukiS. PitchakarnP. YodkeereeS. NaikiT. TakahashiS. LimtrakulP. Curcumin-loaded PLGA nanoparticles conjugated with anti- P-glycoprotein antibody to overcome multidrug resistance.Asian Pac. J. Cancer Prev.201415219249925810.7314/APJCP.2014.15.21.924925422208
     [Google Scholar]
  32. LuY. WangJ. LiuL. YuL. ZhaoN. ZhouX. LuX. Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.Tumour Biol.201739410.1177/101042831769835328443468
     [Google Scholar]
  33. BaekJ.S. ChoC.W. A multifunctional lipid nanoparticle for co-delivery of paclitaxel and curcumin for targeted delivery and enhanced cytotoxicity in multidrug resistant breast cancer cells.Oncotarget2017818303693038210.18632/oncotarget.1615328423731
     [Google Scholar]
  34. WangY. GaoD. LiuY. GuoX. ChenS. ZengL. MaJ. ZhangX. TianZ. YangZ. Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine.Bioact. Mater.2021661513152710.1016/j.bioactmat.2020.11.01633294730
     [Google Scholar]
  35. KimK.R. YouS.J. KimH.J. YangD.H. ChunH.J. LeeD. KhangG. Theranostic potential of biodegradable polymeric nanoparticles with paclitaxel and curcumin against breast carcinoma.Biomater. Sci.20219103750376110.1039/D1BM00370D33870964
     [Google Scholar]
  36. YaoQ. GutierrezD.C. HoangN.H. KimD. WangR. HobbsC. ZhuL. Efficient codelivery of paclitaxel and curcumin by novel bottlebrush copolymer-based micelles.Mol. Pharm.20171472378238910.1021/acs.molpharmaceut.7b0027828605595
     [Google Scholar]
  37. GaoJ. FanK. JinY. ZhaoL. WangQ. TangY. XuH. LiuZ. WangS. LinJ. LinD. PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden.Eur. J. Pharm. Sci.201914010507010.1016/j.ejps.2019.10507031518679
     [Google Scholar]
  38. TianN. ShangguanW. ZhouZ. yaoY. FanC. CaiL. Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma.J. Cancer201910246074608710.7150/jca.3342131762817
     [Google Scholar]
  39. SreekanthC.N. BavaS.V. SreekumarE. AntoR.J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.Oncogene201130283139315210.1038/onc.2011.2321317920
     [Google Scholar]
  40. HanahanD. WeinbergR.A. Hallmarks of cancer: the next generation.Cell2011144564667410.1016/j.cell.2011.02.01321376230
     [Google Scholar]
  41. ZhanY. ChenY. LiuR. ZhangH. ZhangY. Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling.Arch. Pharm. Res.20143781086109510.1007/s12272‑013‑0311‑324318305
     [Google Scholar]
  42. AttiaY.M. El-KershD.M. AmmarR.A. AdelA. KhalilA. WalidH. EskanderK. HamdyM. RedaN. MohsenN.E. Al-ToukhyG.M. MansourM.T. ElmazarM.M. Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer.Chem. Biol. Interact.202031510886510.1016/j.cbi.2019.10886531628941
     [Google Scholar]
  43. WangW. NagS. ZhangR. Targeting the NFκB signaling pathways for breast cancer prevention and therapy.Curr. Med. Chem.201422226428910.2174/092986732166614110612431525386819
     [Google Scholar]
  44. Quispe-SotoE.T. CalafG.M. Effect of curcumin and paclitaxel on breast carcinogenesis.Int. J. Oncol.20164962569257710.3892/ijo.2016.374127779649
     [Google Scholar]
  45. TommasinoM. AccardiR. CaldeiraS. DongW. MalanchiI. SmetA. ZehbeI. The role of TP53 in cervical carcinogenesis.Hum. Mutat.200321330731210.1002/humu.1017812619117
     [Google Scholar]
  46. DangY.P. YuanX.Y. TianR. LiD.G. LiuW. Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-κB-p53-caspase-3 pathway.Exp. Ther. Med.2015941470147610.3892/etm.2015.224025780454
     [Google Scholar]
  47. BavaS.V. SreekanthC.N. ThulasidasanA.K.T. AntoN.P. CheriyanV.T. PuliyappadambaV.T. MenonS.G. RavichandranS.D. AntoR.J. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism.Int. J. Biochem. Cell Biol.201143333134110.1016/j.biocel.2010.09.01120883815
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673313858240826105305
Loading
Systematic Review and Meta-analysis Indicating Curcumin to Enhance the Synergistic Potential of Paclitaxel and Reduce Cell Viability, Tumor Volume, and Drug Resistance in Different Cancers
Curr. Med. Chem. 32, 9030 (2025); https://doi.org/10.2174/0109298673313858240826105305
/content/journals/cmc/10.2174/0109298673313858240826105305
/content/journals/cmc/10.2174/0109298673313858240826105305
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): cancer; combination therapy; curcumin; meta-analysis; natural product; Paclitaxel

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test